

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 9 JUNE 2025

The Board of Directors (the “**Board**”) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) wishes to announce that at the Extraordinary General Meeting (“**EGM**”) of the Company held on 9 June 2025, the resolution relating to the matter set out in the Notice of EGM dated 23 May 2025 (which superseded the Notice of EGM dated 24 April 2025) was duly passed.

The results of the poll on the resolution put to vote at the EGM are set out below:

No.	Resolution(s) relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	To consider and approve the proposed disposal of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) to Haleon China Co., Ltd. and Haleon CH SARL	337061904	336457024	99.821	530480	0.157	74400	0.022

Details of parties who are required to abstain from voting on the resolution

No party was required to abstain from voting on the resolution tabled at the EGM.

Scrutineer

Pursuant to Rule 704(16) of the Listing Manual, Drewcorp Services Pte Ltd acted as the Company's scrutineer for the EGM.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors
9 June 2025